TargetRx develops anti-cancer therapies that specifically target and overcome drug resistance mechanisms in tumor cells. The company focuses on enhancing treatment efficacy and improving patient outcomes in cancer care.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing drug therapies, leading to treatment failure and poor patient outcomes. Overcoming these resistance mechanisms is critical for improving the effectiveness of cancer treatments.
Solution
TargetRx develops targeted anti-cancer therapies designed to specifically address and overcome drug resistance mechanisms within tumor cells. By focusing on the molecular pathways that enable cancer cells to evade drug effects, TargetRx aims to enhance treatment efficacy and improve patient outcomes. Their approach involves identifying and targeting specific resistance mechanisms, developing novel compounds that circumvent these mechanisms, and delivering these compounds directly to the tumor site. This targeted approach minimizes off-target effects and maximizes the therapeutic impact on drug-resistant cancer cells.
Target Audience
TargetRx's primary customers are oncology researchers, pharmaceutical companies, and ultimately, cancer patients who have developed resistance to standard treatments.
Features
- Identification of key drug resistance mechanisms in various cancer types through advanced molecular profiling.
- Development of novel small molecule inhibitors that selectively target these resistance pathways.
- Targeted drug delivery systems to enhance drug concentration at the tumor site and minimize systemic toxicity.
- Preclinical validation of drug candidates in cell-based and animal models of drug-resistant cancer.
- Clinical trials to evaluate the safety and efficacy of TargetRx's therapies in patients with drug-resistant cancers.